| 93.38 -1.58 (-1.66%) | 09-21 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 121.75 | 1-year : | 134.92 |
| Resists | First : | 104.24 | Second : | 115.51 |
| Pivot price | 93.16  |
|||
| Supports | First : | 86 | Second : | 71.55 |
| MAs | MA(5) : | 94.36 |
MA(20) : | 94.44 |
| MA(100) : | 83.27 |
MA(250) : | 54.24 |
|
| MACD | MACD : | -1 |
Signal : | -1 |
| %K %D | K(14,3) : | 74.3 |
D(3) : | 65.7 |
| RSI | RSI(14): 46.5 |
|||
| 52-week | High : | 115.51 | Low : | 14.89 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ORKA ] has closed below upper band by 47.0%. Bollinger Bands are 62.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 95.89 - 96.54 | 96.54 - 97.07 |
| Low: | 90.64 - 91.25 | 91.25 - 91.76 |
| Close: | 92.47 - 93.48 | 93.48 - 94.32 |
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Mon, 21 Sep 2026
Details on Warrant Exercise and Subsequent Share Sales by Oruka Therapeutics' General Counsel - Kalkine Media
Mon, 21 Sep 2026
Oruka Therapeutics SVP Arjun Agarwal Sells 533 Shares Under Rule 10b5-1 Plan - Kalkine Media
Mon, 21 Sep 2026
Oruka Therapeutics SVP Arjun Agarwal sells $51,034 in ORKA stock By Investing.com - Investing.com South Africa
Fri, 18 Sep 2026
ORKA Stock Is Soaring After Psoriasis Trial Results — Here's Why BTIG Hiked Its Price Target By 94% - Stocktwits
Fri, 18 Sep 2026
Oruka Therapeutics, Inc. (ORKA) Stock Analysis: A 58.6% Potential Upside Beckons Biotech Investors - DirectorsTalk Interviews
Tue, 15 Sep 2026
Oruka Therapeutics CEO Lawrence Klein sells $234,680 in ORKA stock - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 66 (M) |
| Shares Float | 57 (M) |
| Held by Insiders | 1.2 (%) |
| Held by Institutions | 116.5 (%) |
| Shares Short | 8,300 (K) |
| Shares Short P.Month | 8,830 (K) |
| EPS | -2.04 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 18.2 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -13 % |
| Return on Equity (ttm) | -18.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.35 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -101 (M) |
| Levered Free Cash Flow | -65 (M) |
| PE Ratio | -45.78 |
| PEG Ratio | 0 |
| Price to Book value | 5.13 |
| Price to Sales | 0 |
| Price to Cash Flow | -61.27 |
| Dividend | 19.36 |
| Forward Dividend | 0 |
| Dividend Yield | 20.7% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|